Revolutionizing Healthcare.

For Patients, Providers, Pharma, and Payers.
A TechBio Company.
Our Closed loop
Zig’s Approach

Our Purpose

As pioneers in the TechBio field, we envision a future where revolutionary intelligent solutions drive personalized medicine, significantly enhancing outcomes for patients, providers, pharma, and payers.

We create and commercialize closed-loop clinical care solutions with Generative AI, Multi-Modal Digital Biomarkers and One-of-a-Kind Drug Delivery Devices, continuously improving outcomes and advancing the practice of personalized medicine. Our efforts also encompass business model innovation, focusing on reducing inefficiencies, lowering care delivery costs, and achieving better alignment across the value chain.

Addressing Unsustainable Challenges

Inefficient
Individual responses to standard treatment vary, leading to poor outcomes and increased costs.
Workforce
Shortages are increasingly delaying access to essential care, while gaps will continue to grow.
Inequities
Health inequities worsen outcomes, strain resources, and impact social well-being.
Breaches
Elevated privacy and security breaches compromise reduces trust and comprises safety.
Misalignment
Misaligned incentives create inefficiencies, inflate costs, and hinder patient outcomes.
Avoidable
Avoidable high-cost acute care hospitalizations keep driving up healthcare expenses.

We use distinctive approaches and are committed to innovative solutions.

Our focal areas include pioneering science, cutting-edge engineering, risk-based development, and business model innovation.

Our Integrated Lifecycle

We develop closed-loop platforms from product design to manufacturing, guided by our unique risk-based innovation process, leveraging proprietary science and cutting-edge engineering expertise. Our cross-functional development approach unites clinicians, technologists, engineers, AI experts, and real users—patients and providers.

We rigorously validate our drug delivery devices, edge medical devices, clinical decision support systems, AI/ML algorithms, and user experiences through comprehensive evaluations, including human factors, clinical studies, and real-world evidence. Our validation process embraces health diversity, regional variations, and employs advanced validation techniques.

We seek regulatory clearances for our medical-grade, consumer-centric platform technologies, drug delivery systems, digital medical devices and personalized machine learning algorithms.

Clinicians and patients use our products, with payers reimbursing for both the products and the outcomes they deliver, while also contracting with healthcare providers for value-based care through our platforms. We manufacture and deliver these products, and operate the technology platform that powers our closed-loop systems for providers, patients, and pharmacists.

Regulated by the FDA and other global agencies, we operate as a combination product, Software as a Medical Device (SaMD), and medical device company, in full compliance with all relevant standards.

Our Products and Platform

Research and Development

We are researching and developing novel drug delivery devices, intelligent edge medical devices, intelligent decision support, and personalized precision dosing algorithms for several therapeutic areas. *

Platform-Based Approach

Our platform-based approach enables scalable development, cross-platform learnings, and shorter development cycles, thus allowing us to support more patients and providers across multiple therapeutic areas.

*Products in development are investigational products. FDA has not yet evaluated the safety or effectiveness of these products.

Our Collaborations

We adapt best practices from other industries into our business collaboration models, creating a self-reinforcing value proposition that creates value for all stakeholders. 

  • Pharmaceutical Industry
  • High Technology Industry
  • Healthcare Providers
  • Payers and Employers
  • Pharmacy

Join the Movement

Contact our Team Today →